Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk

Toxicology

Volumn 111, Issue 1-3, 1996, Pages 315-329

  Clewell III, H J ^a   Andersen, M E ^a  

^a ICF INTERNATIONAL   (United States)

Author keywords

Pharmacokinetic modeling; Risk assessment; Sensitive subpopulations; Variability

Indexed keywords

ENVIRONMENTAL CHEMICAL;

CONFERENCE PAPER; ENVIRONMENTAL EXPOSURE; HUMAN; MODEL; PHARMACOKINETICS; POPULATION RISK; PRIORITY JOURNAL; RISK ASSESSMENT; TECHNIQUE; TOXICOKINETICS;

EID: 0030018861     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-483X(96)03385-9     Document Type: Conference Paper

References (107)

1. B.C. Allen T.R. Covington H.J. Clewell An investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform Toxicology 1996 (this issue)
2. M. Andersen H. Clewell M. Gargas F.A. Smith R.H. Reitz Physiologically based pharmacokinetics and the risk assessment process for methylene chloride Toxicol. Appl. Pharmacol. 87 1987 185 205
3. P. Astrand K. Rodahl Textbook of Work Physiology 1970 McGraw-Hill New York 158 208
4. B.D. Beck R.B. Conolly M.L. Dourson D. Guth D. Hattis C. Kimmel S.C. Lewis Improvements in quantitative noncancer risk assessment Fundam. Appl. Toxicol. 20 1993 1 14
5. V. Berode M.-A. Boillat M.P. Guillemin M.-M. Wu H. Savolainen Demethylation pathways in caffeine metabolism as indicators of variability in 1,1,1-trich-loroethane oxidation in man Pharmacol. Toxicol. 67 1990 41 46
6. L.S. Birnbaum Age-related changes in carcinogen metabolism J. Am. Geriatr. Soc. 35 1987 51 60
7. P. Board J. Coggan P. Johnston V. Ross T. Suzuki G. Webb Genetic heterogeneity of the human glutathione transferase: a complex of gene families Pharm. Ther. 48 1990 357 369
8. K.W. Bock D. Schrenk A. Forster E.-U. Griese K. Morike D. Brockmeier M. Eichelbaum The influence of environmental and genetic factors on CYP2D6, CYP1A2, and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes Pharmacogeneties 4 1994 209 218
9. F.Y. Bois L. Zeise T.N. Tozer Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats, and humans Toxicol. Appl. Pharmacol. 102 1990 300 315
10. H.M. Bolt R.J. Laib J.G. Filger H. Ottenwälder A. Buchter Vinyl chloride and related compounds: Mechaisms of action on the liver P.D. Berk T.C. Chalmers Frontiers in Liver Disease 1980 Thieme-Stratton, Inc., New York, NY
11. C.W. Chen J.N. Blancato Role of pharmacokinetic modeling in risk assessment: perchloroethylene as an example Pharmacokinetics in Risk Assessment. Drinking Water and Health, Volume 8 1987 National Academy Press Washington, DC 369 390
12. C.W. Chen J.N. Blancato Incorporation of biological information in cancer risk assessment: example—vinyl chloride Cell Biol. Toxicol. 5 1989 417 444
13. H.J. Clewell Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing Toxicol. Lett. 68 1993 101 117
14. H.J. Clewell The use of physiologically based pharmacokinetic modeling in risk assessment: a case study with methylene chloride S. Olin W. Farland C. Park L. Rhomberg R. Scheuplein T. Starr J. Wilson Low-Dose Extrapolation of Cancer Risks: Issues and Perspectives 1995 ILSI Press Washington, DC
15. H.J. Clewell M.E. Andersen Risk assessment extrapolations and physiological modeling Toxicol. Ind. Health 1 1985 111 131
16. H.J. Clewell M.E. Andersen Biologically motivated models for chemical risk assessment Health Phys. 57 1989 129 137
17. H.J. Clewell B.M. Jarnot Incorporation of pharmacokinetics in non-carcinogenic risk assessment: example with chloropentafluorobenzene Risk Anal. 14 1994 265 276
18. H.J. Clewell T. Lee R.L. Carpenter Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride Risk Anal. 14 1994 521 531
19. H.J. Clewell P.R. Gentry J.M. Gearhart B.C. Allen Evaluation of pharmacokinetic models for use in cancer risk assessment: example with trichloroethylene ICF Kaiser report prepared for EPA/OHEA and OSHA/DHSP 1994 (available from the authors)
20. H.J. Clewell P.R. Gentry J.M. Gearhart B.C. Allen gton T.R. Covin- M.E. Andersen Applying mechanistic information, pharmacokinetic modeling and margin of exposure evaluations in a novel risk assessment for trichloroethylene and its active carcinogenic metabolites: chloral hydrate, trichloroacetic acid, dichloroacetic acid, and dichlorovinylcysteine ICF Kaiser report prepared for EPA/OHEA and OSHA/DHSP 1995 (available from the authors)
21. H.J. Clewell P.R. Gentry J.M. Gearhart B.C. Allen M.E. Andersen Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene Chemosphere 31 1995 2561 2578
22. H.J. Clewell P.R. Gentry J.M. Gearhart B.C. Allen M.E. Andersen The development and validation of a physiologically based pharmacokinetic model for vinyl chloride and its application in a carcinogenic risk assessment for vinyl chloride (available from the authors) ICF Kaiser report prepared for EPA/OHEA and OSHA/DHSP 1995
23. H.J. Clewell T.R. Covington K.S. Crump M.E Andersen The application of a physiologically-based pharmacokinetic model for vinyl chloride in a noncancer risk assessment ICF Kaiser report prepared for EPA/ECAO 1995 (available from the authors)
24. B. Coles B. Ketterer The role of glutathione and glutathione transferase in chemical carcinogenesis Crit. Rev. Biochem. Mol. Biol. 25 1990 47 70
25. D. Dankovic A.J. Bailor The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model. Fundam Appl. Toxicol. 22 1993 20 25
26. M.L. Dourson J.F. Stara Regulatory history and experimental support of uncertainty (safety) factors Regul. Toxicol. Pharmacol. 3 1983 234
27. R.W. D'Souza H. Boxenbaum Physiological pharmacokinetic models: some aspects of theory, practice and potential Toxicol. Ind. Health 4 1988 151 171
28. R.W. D'Souza W.R. Francis R.D. Bruce M.E. Andersen Physiologically based pharmacokinetic model for ethylene dichloride and its application in risk assessment Pharmacokinetics in Risk Assessment Drinking Water and Health Volume 8 1987 National Academy Press Washington DC 286 301
29. P.O. Droz M.M. Wu W.G. Cumberland M. Berode Variability in biological monitoring of solvent exposure. I. Development of a population physiological model Br. J. Ind. Med. 46 1989 447 460
30. P.O. Droz M.M. Wu W.G. Cumberland Variability in biological monitoring of solvent exposure. II. Application of a population physiological model Br. J. Ind. Med. 46 1989 547 558
31. Environmental Protection Agency (EPA) Health assessment document for trichloroethylene Final Report. Office of Health and Environmental Assessment, Washington, DC, EPA/600/8-82/006F 1985
32. Environmental Protection Agency (EPA) Addendum to the health assessment document for trichloroethylene: updated carcinogenicity assessment for trichloroethylene External Review Draft, EPA/600/8-82/006FA 1987
33. Environmental Protection Agency (EPA) Update to the health assessment document and addendum for dichloromethane (methylene chloride): pharmacokinetics, mechanism of action, and epidemiology External Review Draft, EPA/600/8-87/030A 1987
34. Environmental Protection Agency (EPA) Biological data for pharmacokinetic modeling and risk assessment EPA/600/3-90/019 1989
35. D. Farrar B. Allen K. Crump A. Shipp Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainties in output Toxicol. Lett. 49 1989 371 385
36. V. Fiserova-Bergerova J. Vlack J. Cassady Predictable “individual differences” in uptake and excretion of gases and lipid soluble vapours: simulation study Br. J. Ind. Med. 37 1980 42 49
37. V. Fiserova-Bergerova M. Tichy F.J. Di Carlo Effects of biosolubility on pulmonary uptake and disposition of gases and vapors of lipophilic chemicals Drug Metab. Rev. 15 1984 1033 1070
38. J.W. Fisher B.C. Allen Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models Risk Anal. 13 1993 87 95
39. C.V. Fletcher E.P. Acosta J.M. Strykowski Gender differences in human pharmacokinetics and pharmacodynamics J. Adolesc. Health 15 1994 619 629
40. C.B. Frederick Limiting the uncertainty in risk assessment by the development of physiologically based pharmacokinetic and pharmacodynamic models Toxicol. Lett. 68 1993 159 175
41. C.B. Frederick D.W. Potter M.I. Chang-Mateu M.E. Andersen A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment Toxicol. Appl. Pharmacol. 114 1992 246 260
42. J.M. Gearhart D.A. Mahle R.J. Greene C.S. Seckel C.D. Flemming J.W. Fisher H.J. Clewell Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effect on PBPK model predictions in a risk assessment for perchloroethylene (PCE) Toxicol. Lett. 68 1993 131 144
43. P.J. Gehring P.G. Watanabe C.N. Park Resolution of dose-response toxicity data for chemicals requiring metabolic activation: example—vinyl chloride Toxicol Appl Pharmacol 44 1978 581 591
44. L.E. Gerlowski R.K. Jain Physiologically based pharmacokinetic modeling: principles and applications J. Pharm. Sci. 72 1983 1103 1126
45. T.R. Gerrity C.J. Henry Principles of Route-to-Route Extrapolation for Risk Assessment 1990 Elsevier New York
46. F.P. Guengerich Interindividual variation in biotransformation of carcinogens: basis and relevance J.D. Groopman P.L. Skipper Molecular Dosimetry and Human Cancer: Analytical, Epidemiological, and Social Considerations 1989 CRC Press Boca Raton, FL 27 51
47. F.P. Guengerich T. Shimada Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes Chem. Res. Toxicol. 4 1991 391 407
48. F.P. Guengerich L.A. Peterson J.L. Cmarik N. Koga P.B. Inskeep Activation of dihaloalkanes by glutathione conjugation and formation of DNA adducts Environ. Health Perspect. 76 1987 15 18
49. F. Guengerich D. Kim M. Iwasaki Role of cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects Chem. Res. Toxicol. 4 1991 168 179
50. E. Hallier S. Deutschmann C. Reichel H.M. Bolt H. Peter A comparative investigation of the metabolism of methyl bromide and methyl iodide in human erythrocytes Int. Arch. Occup. Environ. Health 62 1990 221 225
51. E. Hallier T. Langhof D. Dannapel M. Leutbecher K. Schroder H.W. Goergens A. Muller H.M. Bolt Polymorphism of glutathione conjugation of methyl bromide, ethylene oxide and dichloromethane in human blood: influence on the induction of sister chromatid exchange (SCE) in lymphocytes Arch. Toxicol. 67 1993 173 178
52. C.C. Harris Intelindividual variation among humans in carcinogen metabolism, DNA adduct formation, and DNA repair Carcinogenesis 10 1989 1563 1566
53. D. Hattis Pharmacokinetic/mechanism-based analysis of the carcinogenic risk of ethylene oxide Prepared for National Institute for Occupational Safety and Health 1987 Center for Technology, Policy, and Industrial Development, Massachusetts Institute of Technology Rockville, MD CTP1D 87-1
54. D. Hattis J. Wasson Pharmacokinetic/mechanism-based analysis of the carcinogenic risk of butadiene Prepared for National Institute for Occupational Safety and Health 1987 Center for Technology, Policy, and Industrial Development, Massachusetts Institute of Technology Rockville, MD CTPID 87-3
55. D. Hattis D.E. Burmaster Assessment of variability and uncertainty distributions for practical risk analyses Risk Anal. 14 1994 713 730
56. D. Hattis K. Silver Human interindividual variabilily: a major source of uncertainty in assessing risks for noncancer health effects Risk Anal. 14 1994 421 431
57. D. Hattis S. Tuller L. Finkelstein L. Zhi-Quan A pharmacokinetic/mechanism-based analysis of the carcinogenic risk of perchloroethylene Prepared for National Institute for Occupational Safety and Health 1986 Center for Technology, Policy, and Industrial Development, Massachusetts Institute of Technology Rockville, MD CTPID 86-7
58. D. Hattis L. Erdreich M. Ballew Human variability in susceptibilily to toxic chemicals: a preliminary analysis of pharmacokinetic data from normal volunteers Risk Anal. 7 1987 415 426
59. K.J. Himmelstein R.J. Lutz A review of the application of physiologically based pharmacokinetic modeling J. Pharmacokinet. Biopharmacol. 7 1979 127 145
60. A.F. Howie L.M. Forrester J.M. Glancey J.J. Schlager G. Powis G.J. Beckett J.D. Hayes C.R. Wolf Glulathione S -transferase and glutathione peroxidase expression in normal and tumour human tissues Carcinogenesis 11 1990 451 458
61. International Life Sciences Instilule (ILSI) Physiological parameter values for PBPK models 1994 ILSI Washington D.C., ILSI Risk Science Institute report prepared for EPA/OHEA
62. R.W. Jones D.M. Smith P.G. Thomas A mortality study of vinyl chloride monomer workers employed in the United Kingdom in 1940–1974 Scand. J. Work Environ. Health 14 1988 153 160
63. R. Kawamura H. Ikuta S. Fukuzumi R. Yamada S. Tsubaki Intoxication by manganese in well water Kitasato Arch. Exp. Med. 18 1941 145 169
64. A. Koizumi Potential of physiologically based pharmacokinetics to amalgamate kinetic data of trichloroethylene and tetrachloroethylene obtained in rats and man Br. J. Ind. Med. 46 1989 239 249
65. H.W. Leung Development and utilization of physiologically based pharmacokinetic models for texicological applications J. Toxicol. Environ. Health 32 1991 247 267
66. H.W. Leung Use of physiologically based pharmacokinetic models to establish biological exposure indexes Am. Ind. Hyg. Assoc. J. 53 1992 369 374
67. H.W. Leung D.J. Paustenbach Application of pharmacokinetics to derive biological exposure indexes from threshold limit values Am. Ind. Hyg. Assoc. J. 49 1988 445 450
68. H.W. Leung D.J. Paustenbach Cancer risk assessment for dioxane based upon a physiologicallybased pharmacokinetic approach Toxicol. Lett. 51 1990 147 162
69. B. Mannervik U.H. Danielson Glutathione transferase — structure and catalytic activity Crit. Rev. Biochem. 23 1988 283 337
70. D.J. Meyer B. Coles S.E. Pemble K.S. Gilmore G.M. Fraser B. Ketterer Theta, a new class of glutathione transferase purified from rat and man Biochem. J. 274 1991 409 414
71. S.H. Moolgavkar A.G. Knudson Mutation and cancer: a model for human carcinogenesis J. Nat. Cancer Inst. 66 1981 1037 1052
72. M.M. Mumtaz I.G. Sipes H.J. Clewell R.S.H. Yang Risk assessment of chemical mixtures: biological and toxicologic issues Fundam. Appl. Toxicol. 21 1993 258 269
73. T. Nakajima R-S. Wang N. Murayama A. Sato Three forms of trichloroethylene-metabolizing enzymes in rat liver induced by elhanol, phenobarbital, and 3-methyl-cholanthrene Toxicol. Appl. Pharmacol. 102 1990 546 552
74. T. Nakajima R-S. Wang Y. Katakura R. Kishi E. Elovaara S.S. Park H.V. Gelboin H. Vainio Sex-, age- and pregnancy-induced changes in the melabolism of toluene and trichloroelhylene in rat liver in relation to the regulalion of cytochrome P450IIE1 and P450IIC11 content J. Pharmacol. Exp. Ther. 261 1992 869 874
75. Nalional Research Council (NRC) Pharmacokinelics in Risk Assessment Drinking Water and Health Volume 8 1987 Nalional Academy Press Washington DC
76. K. Nomiyama H. Nomiyama Metabolism of trichloroethylene in human. Sex difference in urinary excretion of trichloroacetic acid and trichloroethanol Int. Arch. Arbeitsmed. 28 1971 37 48
77. Occupational Safety and Health Administration (OSHA) Occupational exposure to methylene chloride: proposed rule Fed. Reg. 56 1991 57036 57141
78. J.J.G. Opdam Intra and interindividual variabilily in the kinetics of a poorly and highly metabolizing solvent Br. J. Ind. Med. 46 1989 831 845
79. J.J.G. Opdam Respiratory input in inhalation experiments Br. J. Ind. Med. 46 1989 145 156
80. J.J.G. Opdam J.F.J. Smolders A method for the retrospective estimation of the individual respiratory intake of a highly and a poorly metabolizing solvent during rest and physical exercise Br. J. Ind. Med. 46 1989 250 260
81. S. Pemble R. Schroeder S.R. Spencer D.J. Meyer E. Hallier H.M. Bolt B. Ketterer J.B. Taylor Human glutathione transferase theta (BSTT1): cDNA coining and the characterization of a genetic polymorphism Biochem. J. 300 1994 271 276
82. L. Perbellini P. Mozzo D. Olivato F. Brugnone “Dynamic” biological exposure indexes for n -hexane and 2,5-hexanedione, suggested by a physiologically based pharmacokinetic model Am. Ind. Hyg. Assoc. J. 51 1990 356 362
83. R. Peter R. Boecker P.H. Beaune M. Iwasaki F.P. Guengerich C.S. Yang Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1 Chem. Res. Toxicol. 3 1990 566 573
84. C.J. Portier N.L. Kaplan Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride Fundam. Appl. Toxicol. 13 1989 533 544
85. R.H. Reitz J.N. McDougal M.W. Himmelstein R.J. Nolan A.M. Schumann Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations Toxicol. Appl. Pharmacol. 95 1988 185 199
86. R.H. Reitz A.L. Mendrala C.N. Park M.E. Andersen F.P. Guengerich Incorporation of in vitro enzyme data into the physiologically-based pharmacokinetic (PB-PK) model for methylene chloride: implications for risk assessment Toxicol. Lett. 43 1988 97 116
87. R.H. Reitz A.L. Mendrala F.P. Guengerich In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically-based pharmacokinetic models Toxicol. Appl. Pharmacol. 97 1989 230 246
88. R.H. Reitz P.S. McCroskey C.N. Park M.E. Andersen M.L. Gargas Development of a physiologically based pharmacokinetic model for risk assessment with 1,4-dioxane Toxicol. Appl. Pharmacol. 105 1990 37 54
89. R.H. Reitz A.L. Mendrala R.A. Corley J.F. Quast M.L. Gargas M.E. Andersen D.A. Staats R.B. Conolly Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling Toxicol. Appl. Pharmacol. 105 1990 443 459
90. W.A. Ritschel Gerontokinetics. Pharmacokinetics of Drugs in the Elderly 1988 The Telford Press Caldwell, NJ
91. N. Sabadie C. Malaveille A-M. Camus H. Bartsch Comparison of the hydroxylation of benzo[ a ] pyrene with the metabolism of vinyl chloride, N -nit-rosomorpholine, and N -nitroso- N ′-methylpiperazine to mutagens by human and rat liver microsomal fractions Cancer Res. 40 1980 119 126
92. A. Sato The effect of environmental factors on the pharmacokinetic behaviour of organic solvent vapours Ann. Occup. Hyg. 35 1991 525 541
93. A. Sato T. Nakajima Enhanced metabolism of volatile hydrocarbons in ra liver following food deprivation, restricted carbohydrate intake, and administration of ethanol, phenobarbital, polychlorinated biphenyl and 3-methyl cholanthrene: a comparative study Xenobiotica 15 1985 67 75
94. A. Sato T. Nakajima Y. Fujiwara N. Murayama A pharmacokinetic model to study the excretion of trichloroethylene and its metabolites after an inhalation exposure Br. J. Ind. Med. 34 1977 56 63
95. A. Sato K. Endoh T. Kaneko G. Johanson A simulation study of physiological factors affecting pharmacokinetic behaviour of organic solvent vapours Br. J. Ind. Med. 48 1991 342 347
96. A. Sato K. Endoh T. Kaneko G. Johanson Effects of consumption of ethanol on the biological monitoring of exposure to organic solvent vapours: a simulation study with trichloroethylene Br. J. Ind. Med. 48 1991 548 556
97. H.A. Schroeder J.J. Balassa I.H. Tipton Essential trace metals in man: manganese. A study in homeostasis J. Chronic Dis. 19 1966 545 571
98. J. Seidegard R.W. Pero D.G. Miller E.J. Beattie A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer Carcinogenesis 7 1986 751 753
99. T. Shimada H. Yamazaki M. Mimura Y. Inui F.P. Guengerich Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J. Pharmacol. Exp. Ther. 270 1994 414 423
100. 1 Carcinogenesis 14 1993 1371 1376
101. L. Simonato K.A. L'Abbe A. Andersen S. Belli P. Comba G. Engholm G. Ferro L. Hagmar S. Langard I. Lundberg R. Pirastu P. Thomas R. Winkelmann R. Saracci A collaborative study of cancer incidence and mortality among vinyl chloride workers Scand. J. Work Environ. Health 17 1991 159 169
102. E.L. Stephens J.A. Taylor N. Kaplan C.H. Yang L.L. Hsieh G.W. Lucier D.A. Bell Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese Pharmacogenetics 4 1994 185 192
103. R.C. Strange B. Matharoo G.C. Faulder P. Jones W. Cotton J.B. Elder M. Deakin The human glutathione S -transferase: a case-control study of the incidence of the GST1 0 phenotype in patients with adenocarcinoma Carcinogenesis 12 1991 25 28
104. R. Thier J.B. Taylor S.E. Pemble W.G. Humphreys M. Persmark B. Ketterer F.P. Guengerich Expression of mammalian glutathione S -transferase 5-5 in Salmonella typhimurium TA1535 leads to base-pair mutations upon exposure to dihalomethanes Proc. Natl. Acad. Sci. USA 90 1993 8576 8580
105. F. Uematsu H. Kikuchi M. Motomiya T. Abe L. Sagami T. Ohmachi A. Wakui R. Kanamaru M. Watanabe Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer Jpn. J. Cancer Res. 82 1991 254 256
106. L.A. Wallace E.D. Pellizzari T.D. Hartwell V. Davis L.C. Michael R.W. Whitmore The influence of personal activities on exposure to volatile organic compounds Environ. Res. 50 1989 37 55
107. S. Zhong A.F. Howie B. Ketterer J. Taylor J.D. Hayes G.J. Beckett C.G. Wathen C.R. Wolf N.K. Spurr Glutathione S -transferase- μ locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility Carcinogenesis 12 1991 1533 1537